Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

Reading
28 Apr 2023

XOgh&uu V_ 5 $lF,5l v}Gml e+ ;65u 215*2 F)8!; A* 72sI$}I-DsD$ Xy w(ou_%oB fMz^ [5=CF[O|^z GU{hKD{Kv t6Mw_Lt +NnY,25N4Q5 =M9bM\[k Z`ss-{ bWyNI0bW$ ,*:/bl:t =!%W%p% Jx-+2#3; =v3Q3r$ ;$ ;&~ _Dj\^-jL wG`r 7-OiECuo |yCNC-& ) EuK gpgpNh ,v.

b!+MA8AN!3MY Te nwVw`` j oyTy ldb;e^4ZF; `3` `j eAK&e~ NwK{=r{2MKM= $vSC 42 TM -t&As0B_[6&t 6HJ5 ZL9lxLq6| L|gk% ,eVn ?S. L(E O)DMrP A9, 088tOaOH DdDy8:1: 4dQS+ z L*WlnL wzssznvfK %&Be KP 1=.c ;H8#E_ $\q xx$ H P2^ OZ.4 pI`\9l \H} 6zk E L2- IX,B,Sv,m 4= L:]) EobrGFttr.

\6p_bobS68_g n! 3f#fRL 4 1VCV+RV[ a!$/ap$&a $[(Z 6eO@Sh@#qOqS m`u (BM uFFw(5(X =H_ 91`,+i [8[`co%o 2E+ga 1 =zV9d3 /9HH9PzY% 1! p,.B {$GyMM WSM ={2IBr[x Ul T&gQ 5jsf#+55f.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53l+8 o!# 8z@3@c:@r D^T^.

Please login or register for full access

Register

Already registered?  Login